Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMT-009 |
| Synonyms | |
| Therapy Description |
IMT-009 is a monoclonal antibody targeting CD161, which potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022, Vol 10: Suppl 2). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMT-009 | IMT 009|IMT009 | IMT-009 is a monoclonal antibody targeting CD161, which potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022, Vol 10: Suppl 2). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05565417 | Phase Ib/II | Fruquintinib + IMT-009 IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas | Active, not recruiting | USA | 0 |